Cover Image
市場調查報告書

製藥生物科技的技術平台的演進

Evolving Technology Platforms in Pharma-Biotech

出版商 Technical Insights (Frost & Sullivan) 商品編碼 346463
出版日期 內容資訊 英文 87 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
製藥生物科技的技術平台的演進 Evolving Technology Platforms in Pharma-Biotech
出版日期: 2015年11月30日 內容資訊: 英文 87 Pages
簡介

本報告提供生物醫藥品的開發相關調查分析,以藥物研發初期階段之後的藥物為焦點,R&D組合與預算分析,環境分析 (技術性課題,商務課題,新興市場需求) 、產業的最佳業務實踐與策略性考察 (業績,合作夥伴關係、聯盟,研發產品線等) 、R&D組合的策略性評估相關的系統性資訊。

第1章 摘要整理

第2章 藥物研發、開發概要

  • 藥物研發、開發過程
  • 開發週期
  • 經營模式和參與企業
  • 經營模式的演進

第3章 產業環境的策略性評估

  • 藥物研發、開發焦點
  • 全球支出
  • 製造和商業化

第4章 基準模式與前提條件

  • R&D基準:架構
  • R&D基準:主要的優勢 (各企業)
  • R&D基準:要點

第5章 案例研究

  • 競爭情形
  • 中成為核心的治療領域
  • 主要的事實
  • 藥理學流程
  • 開發平台
  • 智慧財產權
  • 損益清單
  • 研究開發等

第6章 關於Frost&Sullivan

目錄
Product Code: D69C-01-00-00-00

The road ahead toward precision medicine

The continued development of new treatments associated with the demographic trends and public health considerations is essential. The biopharmaceutical industry is one of the most research intensive sectors in developed nations. Investments are more than USD 125 billion, especially in early stages development phases, including the processes of discovering and developing new medicines.

Biopharmaceutical innovation has played a major role in the improvement of both length and quality of life during the past decade, considerably reducing the disease burden for individuals and the society. Groundbreaking advances in the scientific understanding of the underlying mechanisms of disease are paving the way for precision medicine for the upcoming years. Indeed, the promise of personalized medicine is becoming a reality generating notable improvements in human health and the potential to reduce the socioeconomic burden of disease.

This research service (RS) depicts the current landscape of biopharmaceutical development, focusing on medicines that have progressed beyond early stage development and have recently entered clinical testing in human volunteers or first-in-human studies.

The RS also includes:

  • R&D portfolio and budgetary analysis
  • Environmental analysis, depicting the key technical challenges, key business challenges, and emerging market needs
  • Industry best practices and strategic insights, measuring performance, assessment of partnerships and alliances and R&D pipeline by milestones
  • Strategic evaluation of R&D portfolio

Table of Contents

1. EXECUTIVE SUMMARY

Executive Summary

  • 1. Research Scope
  • 2. Research Methodology
  • 3. Key Findings

2. DRUG DISCOVERY AND DEVELOPMENTA SNEAK PREVIEW

Drug Discovery and DevelopmentA Sneak Preview

  • 1. Drug Discovery and Development Process
  • 2. Development Cycle Times
  • 3. Business Models and Participants
  • 4. Business Model Evolution

3. STRATEGIC ASSESSMENT OF THE INDUSTRY ENVIRONMENT

Strategic Assessment of the Industry Environment

  • 1. Drug Discovery and Development Focus
  • 2. Drug Discovery and Development Focus (continued)
  • 3. Global Expenditures
  • 4. Manufacturing and Commercialization
  • 5. Manufacturing and Commercialization (continued)

4. BENCHMARKING MODEL AND ASSUMPTIONS

Benchmarking Model and Assumptions

  • 1. R&D Benchmarking: Framework
  • 2. R&D Benchmarking: Main Strengths by Company
  • 3. R&D Benchmarking: Main Strengths by Company (continued)
  • 4. R&D Benchmarking: Key Takeaways

5. CASE REPRESENTATIVE STUDIES:ABBVIE - AMGEN - BAYER - ROCHE

Case Representative Studies:AbbVie - Amgen - Bayer - Roche

  • 1. Competitor Landscape
  • 2. Core Therapeutic Areas
  • 3. Principal Facts
  • 4. Pharmacology Process
  • 5. Pharmacology Process (continued)
  • 6. Pharmacology Process (continued)
  • 7. Pipeline
  • 8. Pipeline (continued)
  • 9. Intellectual Property
  • 10. Income Statement: Explanatory Comments
  • 11. Income Statement: Costs and Expenses
  • 12. Research and Development
  • 13. Emerging Markets
  • 14. Partnerships and Acquisitions
  • 15. Competitor Landscape
  • 16. Core Therapeutic Areas
  • 17. Principal Facts
  • 18. Pipeline
  • 19. Pipeline (continued)
  • 20. Income Statement: Costs and Expenses
  • 21. Research and Development
  • 22. Big Pharma Strategy Assessment (continued)
  • 23. Discovery Research Model
  • 24. Strategic Roadmap
  • 25. Key Insights
  • 26. Competitor Landscape
  • 27. Competitor Landscape
  • 28. Core Therapeutic Areas
  • 29. Principal Facts
  • 30. Pipeline
  • 31. Pipeline (continued)
  • 32. Pharmacology Process
  • 33. Pharmacology Process (continued)
  • 34. Pharmacology Process (continued)
  • 35. Pharmacology Process (continued)
  • 36. Income Statement: Costs and Expenses
  • 37. Research and Development
  • 38. Emerging Markets
  • 39. Competitor Landscape
  • 40. Core Therapeutic Areas
  • 41. Principal Facts
  • 42. Pipeline
  • 43. Pipeline (continued)
  • 44. Pipeline (continued)
  • 45. Pipeline (continued)
  • 46. Pipeline (continued)
  • 47. Pharmacology Process
  • 48. Pharmacology Process (continued)
  • 49. Pharmacology Process (continued)
  • 50. Income Statement: Costs and Expenses
  • 51. Research and Development
  • 52. Innovation Model
  • 53. Emerging Markets
  • 54. Partnerships
  • 55. Legal Disclaimer

6. THE FROST & SULLIVAN STORY

The Frost & Sullivan Story

  • 1. The Frost & Sullivan Story
  • 2. Value Proposition: Future of Your Company & Career
  • 3. Global Perspective
  • 4. Industry Convergence
  • 5. 360° Research Perspective
  • 6. Implementation Excellence
  • 7. Our Blue Ocean Strategy
Back to Top